e-Therapeutics plc is engaged in the discovery and development of drugs through its proprietary platform in network pharmacology. The company focuses on the discovery of drugs for cancer and degenerative diseases of the nervous system. Its drug candidates include ETS2101, which is in Phase I clinical trial for the treatment of brain cancer in the United States, and for the treatment of solid tumors in the United Kingdom; ETS6103, a Phase IIb trial product for depressive disorders; and ETX1153c, an anti-infective drug candidate that is in preclinical stage for the treatment of C. difficile infection. The company was founded in 2001 and is based in Long Hanborough, the United Kingdom.
e-therapeutics plc (ETX:London)
Network Pharmacology Centre
17 Blenheim Office Park
Long Hanborough, OX29 8LN
Phone: 44 1993 880 000
Fax: 44 1993 880 207www.etherapeutics.co.uk
|No competitor information is available for ETX.|
|View Industry Companies|
|Price/Cash Flow||NM||Not Meaningful|
Sponsored Financial Commentaries
To contact E-THERAPEUTICS PLC, please visit www.etherapeutics.co.uk. Company data is provided by Capital IQ. Please use this form to report any data issues.